Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Δ9-Tetrahydrocannabinol and Cannabidiol Differentially Regulate Intraocular Pressure.

Miller S, Daily L, Leishman E, Bradshaw H, Straiker A.

Invest Ophthalmol Vis Sci. 2018 Dec 3;59(15):5904-5911. doi: 10.1167/iovs.18-24838.

2.

A Brief Background on Cannabis: From Plant to Medical Indications.

Klumpers LE, Thacker DL.

J AOAC Int. 2018 Aug 23. doi: 10.5740/jaoacint.18-0208. [Epub ahead of print]

PMID:
30139415
3.

[Should ophtalmologists recommend medical cannabis to patients with glaucoma?]

Mouhammad ZA, Kolko M.

Ugeskr Laeger. 2018 Jul 16;180(29). pii: V11170861. Danish.

PMID:
30020072
4.

Cannabis and intractable chronic pain: an explorative retrospective analysis of Italian cohort of 614 patients.

Fanelli G, De Carolis G, Leonardi C, Longobardi A, Sarli E, Allegri M, Schatman ME.

J Pain Res. 2017 May 22;10:1217-1224. doi: 10.2147/JPR.S132814. eCollection 2017.

5.
6.

Phytochemistry of Cannabis sativa L.

ElSohly MA, Radwan MM, Gul W, Chandra S, Galal A.

Prog Chem Org Nat Prod. 2017;103:1-36. doi: 10.1007/978-3-319-45541-9_1. Review.

PMID:
28120229
7.

Endocannabinoid System: A Multi-Facet Therapeutic Target.

Kaur R, Ambwani SR, Singh S.

Curr Clin Pharmacol. 2016;11(2):110-7. Review.

PMID:
27086601
8.

Medical marijuana in neurology.

Benbadis SR, Sanchez-Ramos J, Bozorg A, Giarratano M, Kalidas K, Katzin L, Robertson D, Vu T, Smith A, Zesiewicz T.

Expert Rev Neurother. 2014 Dec;14(12):1453-65. doi: 10.1586/14737175.2014.985209. Review.

PMID:
25427150
9.

The prevalence and incidence of medicinal cannabis on prescription in The Netherlands.

Hazekamp A, Heerdink ER.

Eur J Clin Pharmacol. 2013 Aug;69(8):1575-80. doi: 10.1007/s00228-013-1503-y. Epub 2013 Apr 16.

PMID:
23588562
10.

Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities.

Pertwee RG.

Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3353-63. doi: 10.1098/rstb.2011.0381. Review.

11.

Poly-ε-caprolactone microspheres as a drug delivery system for cannabinoid administration: development, characterization and in vitro evaluation of their antitumoral efficacy.

Hernán Pérez de la Ossa D, Ligresti A, Gil-Alegre ME, Aberturas MR, Molpeceres J, Di Marzo V, Torres Suárez AI.

J Control Release. 2012 Aug 10;161(3):927-32. doi: 10.1016/j.jconrel.2012.05.003. Epub 2012 May 10.

PMID:
22580111
12.

Neuroprotective effects of cannabidiol in endotoxin-induced uveitis: critical role of p38 MAPK activation.

El-Remessy AB, Tang Y, Zhu G, Matragoon S, Khalifa Y, Liu EK, Liu JY, Hanson E, Mian S, Fatteh N, Liou GI.

Mol Vis. 2008;14:2190-203. Epub 2008 Dec 3. Retraction in: Mol Vis. 2014;20:1227.

13.

Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study.

Tomida I, Azuara-Blanco A, House H, Flint M, Pertwee RG, Robson PJ.

J Glaucoma. 2006 Oct;15(5):349-53.

PMID:
16988594
14.

Neuroprotective effect of (-)Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite.

El-Remessy AB, Khalil IE, Matragoon S, Abou-Mohamed G, Tsai NJ, Roon P, Caldwell RB, Caldwell RW, Green K, Liou GI.

Am J Pathol. 2003 Nov;163(5):1997-2008.

15.

Medicinal use of cannabis: history and current status.

Kalant H.

Pain Res Manag. 2001 Summer;6(2):80-91.

PMID:
11854770
16.

Cannabinoids in clinical practice.

Williamson EM, Evans FJ.

Drugs. 2000 Dec;60(6):1303-14. Review.

PMID:
11152013
17.

Cannabinoids in glaucoma: a primary screening procedure.

Elsohly MA, Harland E, Murphy JC, Wirth P, Waller CW.

J Clin Pharmacol. 1981 Aug-Sep;21(S1):472S-478S.

PMID:
6271842
18.

Toward drugs derived from cannabis.

Mechoulam R, Carlini EA.

Naturwissenschaften. 1978 Apr;65(4):174-9. Review.

PMID:
351429

Supplemental Content

Loading ...
Support Center